ETC-vaccine: Phase III

ACTI said its 671-patient Phase III trial in Guatemala and Mexico did not meet its primary end point of protecting travelers from diarrhea caused by ETEC infections. A trend towards protection from moderate to severe diarrhea was observed, however. ACTI said it will not submit its European marketing application for the vaccine this year, as was planned. ...